Last Updated : May 18, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Trajenta | Linagliptin | Diabetes mellitus, type 2 | List with clinical criteria and/or conditions | Complete | ||
Incivek | Telaprevir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
Edurant | Rilpivirine | HIV infection | List | Complete | ||
Aclasta | Zoledronic acid | Osteoporosis | List with clinical criteria and/or conditions | Complete | ||
Votrient | Pazopanib hydrochloride | Metastatic Renal Cell Carcinoma | Reimburse | Complete | ||
Targin | Oxycodone HCI / naloxone HCI | Pain, moderate to severe and relief of opioid-induced constipation | Do not list | Complete | ||
Abstral | Fentanyl citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
Xarelto | Rivaroxaban | Venous thromboembolism, prevention | N/A | Complete | ||
XGEVA | Denosumab | Prevention of skeletal-related events due to bone metastases from solid tumours | List with clinical criteria and/or conditions | Complete |